Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07502443 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
A Phase 3 study, sponsored by Alkermes.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
NCT07502443: Recruiting Phase 3 study, sponsored by Alkermes.
NCT07502443 is a Phase 3 study that is actively recruiting participants, run by Alkermes. The registered enrollment target is 176 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07502443, a Phase 3 study, is actively recruiting participants, sponsored by Alkermes.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
Study Summary
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Interventions
- DRUG Placebo
- DRUG ALKS 2680 Dose 1
- DRUG ALKS 2680 Dose 2
- DRUG ALKS 2680 Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
What NCT07502443 shows while recruiting
NCT07502443 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07502443 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07502443 about?
NCT07502443 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2". The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
What is the current status of trial NCT07502443?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2026-04-22. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07502443?
The interventions under investigation include: Placebo (DRUG), ALKS 2680 Dose 1 (DRUG), ALKS 2680 Dose 2 (DRUG), ALKS 2680 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT07502443?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07502443's enrollment target sits among peer trials
176 1438th of 2000 higher than 561 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI